Stuart Therapeutics Announces New Relationship with Ora Clinical, Inc.

Welcome To Stuart Therapeutics

Stuart Therapeutics, established in 2017 is developing PolyCol, a unique therapeutic platform that offers improvements in health outcomes for a wide variety of medical and veterinary conditions.

PolyCol is based on patented research from a major U.S. university, combined with additional intellectual property developed by Stuart Therapeutics. The company has developed applications for PolyCol in treating certain ophthalmic, gastrointestinal, inflammatory, and oncology conditions.

The initial product under development that takes advantage of PolyCol is ST-100, the first therapeutic for dry eye syndrome that addresses both the immediate painful symptoms, as well as the underlying inflammatory causes.

Indications

Stuart Therapeutics’ first drug candidate is ST-100, a novel therapeutic in drop formulation for Dry Eye Disease (DED). Unlike most therapeutic solutions for DED, ST-100 is a fast acting, broadly applicable option for patients that has shown an ability to provide complete corneal healing in less than 24 hours in animal studies. ST-100 is believed to act by directly healing and aligning exposed and damaged collagen fibers in moderate to severe DED sufferers, providing an ideal environment for epithelial recovery and relief from painful symptoms.

Latest News

25 Feb. 2019
Stuart Therapeutics, Inc. Announces Relationship with Ora, Inc. for IND Preparation, Regulatory Advisory, and Clinical Trial Services for ST-100

STUART, FLORIDA February 25, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical therapeutic development company, today announced that it has retained the services of Ora®, Inc., the premier ophthalmology Contract Research Organization (“CRO”) globally, to provide various product development, IND preparation, regulatory advisory and clinical trial services for STUART’s first drug candidate, ST-100. ST-100 is

Read More
04 Oct. 2018
Stuart Therapeutics Announces Corneal Epithelial Healing and Organization Pre-Clinical Results for its Potential Dry Eye Therapeutic

October 4th, 2018, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced important pre-clinical in vivo proof of concept results for its collagen mimetic polypeptide therapeutic, PolyColTM (PolyCol).  The company announced additional important results from its mouse eye wound tests.  Previous results showed statistically significant results

Read More
17 Sep. 2018
Stuart Therapeutics Announces Important Pre-Clinical Results for ST-100

September 17th, 2018, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced important pre-clinical in vivo proof of concept results for its collagen mimetic polypeptide therapeutic, PolyColTM (PolyCol).  Mouse eye wound tests conducted at the University of Louisville demonstrated rapid, high quality healing of corneal wounds,

Read More